You are here: Home » Current Affairs » Coronavirus » News
Business Standard

PIL in HC seeks permission for sale of Remdesivir in domestic markets

A PIL in the Delhi High Court has urged it to direct the Centre to permit sale of Remdesivir, used in Covid-19 treatment, by those pharmaceutical companies which manufacture it solely for the purpose

Topics
Remdesivir | PIL | Delhi High Court

Press Trust of India  |  New Delhi 

Remdesivir, coronavirus, covid-19, drugs, medicine, health

A in the has urged it to direct the Centre to permit sale of Remdesivir, used in COVID-19 treatment, by those pharmaceutical companies which manufacture it solely for the purpose of export so that the drug is easily available in the market for needy patients.

The petition, which is listed for hearing on Monday before a bench of Chief Justice D N Patel and Justice Jasmeet Singh, has said that there are more than 25 companies in India which manufacture the medicine, but only six to eight of them are permitted to sell it in the domestic market and the rest were producing it for exports alone.

The petitioner, Dincur Bajaj, has contended that since export of has been banned by the Centre, the companies which were producing it for export be permitted to manufacture and sell it in the domestic market.

"It is pertinent to mention that the scarcity of Remdesiviris causing its extensive black-marketing and the black marketers are charging prices up to Rs 1,00,000 per vial, due to its non-availability," Bajaj, who is a lawyer and the Joint Secretary of the Bar Association, has said in his plea.

The petition, filed through advocates Amit Saxena and Imran Ali, has also said that huge stocks of the medicine are lying at the ports for being exported and the same can be sold in the domestic market.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Sun, May 02 2021. 20:07 IST
RECOMMENDED FOR YOU